



**Uptravi (Selexipag)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
 AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





Upravi (Selexipag) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Pulmonary arterial hypertension <input type="checkbox"/> Other diagnosis: _____ ICD-10 _____		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
<p>Clinical Information: Is Upravi being prescribed by a pulmonologist, cardiologist, nephrologist, or rheumatologist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1)? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Select if the patient's pulmonary arterial hypertension (PAH) was caused by the following:</p> <ul style="list-style-type: none"> <input type="checkbox"/> Idiopathic/Primary PAH <input type="checkbox"/> Drug- and toxin-induced <input type="checkbox"/> Connective tissue disease (e.g., Lupus/SLE, RA scleroderma, systemic sclerosis, CREST syndrome, polymyositis, polyarteritis nodosa, mixed connective tissue disease) <input type="checkbox"/> HIV infection <input type="checkbox"/> Portal hypertension <input type="checkbox"/> Congenital heart disease <input type="checkbox"/> Schistosomiasis <input type="checkbox"/> Chronic hemolytic anemia <p>Does the patient experience WHO Functional Class II through IV symptoms? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>Select if the patient's cardiac catheterization report meets any of the following:*</p> <ul style="list-style-type: none"> <input type="checkbox"/> MPAP 25 mmHg or greater + PCWP less than 19 mmHg/LVEDP not reported <input type="checkbox"/> MPAP 25 mmHg or greater + LVEDP less than 19 mmHg/PCWP not reported <input type="checkbox"/> MPAP 25 mmHg or greater + PCWP less than 19 mmHg + LVEDP less than 19 mmHg <p><i>*Please provide a copy of the report.</i></p> <p>Has the patient tried and had an inadequate response or intolerance to PDE5 inhibitor (i.e. Revatio, Adcirca) OR Adempas (riociguat)?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please provide documentation.</i></p> <p>Does the patient have a contraindication to treatment with BOTH a PDE5 inhibitor (i.e. Revatio, Adcirca) and Adempas (riociguat)?* <input type="checkbox"/> Yes <input type="checkbox"/> No <i>*Please submit documentation of the contraindication.</i></p>		





**Upravi (Selexipag)
Prior Authorization Request Form**



Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

Has the patient tried and had an inadequate response or intolerance to an endothelin receptor antagonist [e.g., Letairis (ambrisentan), Opsumit (macitentan), or Tracleer (bosentan)]?* Yes No

**Please provide documentation.*

Does the patient have a contraindication to treatment with an endothelin receptor antagonist [e.g., Letairis (ambrisentan), Opsumit (macitentan), or Tracleer (bosentan)]?* Yes No

Please submit documentation of the contraindication.

Will Upravi be taken in combination with a prostanoid/prostacyclin analogue (e.g., epoprostenol, iloprost, treprostinil)? Yes No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program; c/o Magellan Health, Inc.
4801 E. Washington Street, Phoenix, AZ 85034
Phone: 877-228-7909

